Using Observational Analysis of Multiple Sclerosis Relapse to Design Outcomes-Based Contracts for Disease-Modifying Drugs: A Feasibility Assessment. Lage MJ, Carroll CA, Fairman KA J Med Econ. 2013 Jul 12. PMID: 23844620. Abstract CommentRecommendBookmarkWatch